FRI0315 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Biib059, a Monoclonal Antibody Targeting Bdca2 Following Intravenous (IV) and Subcutaneous (SC) Single or Multiple Doses Administration in Healthy Volounteers (HV) and Subjects With Active Systemic Lupus Erythematosus (SLE)
doi 10.1136/annrheumdis-2018-eular.2619
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2018
Authors
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism